ADC Therapeutics is positioning Zynlonta for a label expansion with new Phase II data showing that the treatment can elicit high rates of complete response in patients with relapsed or refractory marginal zone lymphoma.
Tag Archive for: ADC Therapeutics
The move comes after a review of data of 40 patients in the trial indicated potentially excessive respiratory-related events, including seven deaths and five serious adverse events.
Just because it’s mid-July, that doesn’t mean clinical trial announcements are slowing down. This article reviews some of the more intriguing stories of the past week.